Klotho
alpha-Klotho, sKlotho, long-release recombinant Klotho
Klotho (alpha-Klotho, sKlotho, long-release recombinant Klotho) is a longevity & bioregulators research compound. Alpha-Klotho is an anti-ageing protein made mostly in the kidney and the choroid plexus. A soluble form is shed into blood and CSF. It is the obligate co-receptor that lets FGF23 signal, which is how it governs phosphate and vitamin D handling, and separately it dampens insulin/IGF-1 and Wnt signalling and raises resistance to oxidative stress. Klotho falls with age and falls further in chronic kidney disease.
Klotho quick facts
| Reported research dose | 20mcg vial — see the full breakdown; no human dose exists |
| Route | Subcutaneous |
| Frequency | Undefined |
| Half-life | Native soluble Klotho is cleared within hours; the LR construct carries an albumin-binding group intended to hold cellular activity for up to ~19 days (vendor claim, not independently published) |
| Forms | Injectable |
| Evidence level | Theoretical — no human administration data |
The mouse genetics here are about as strong as ageing biology gets — and there is still not one human administration study. Treat any number as an extrapolation. It is also 20mcg, not milligrams: this is a protein dosed a thousand-fold lower than the peptides next to it, and confusing the units would be the dangerous error.
How Klotho works
Alpha-Klotho is an anti-ageing protein made mostly in the kidney and the choroid plexus. A soluble form is shed into blood and CSF. It is the obligate co-receptor that lets FGF23 signal, which is how it governs phosphate and vitamin D handling, and separately it dampens insulin/IGF-1 and Wnt signalling and raises resistance to oxidative stress. Klotho falls with age and falls further in chronic kidney disease.
Proposed benefits
Cognitive ageing, kidney and vascular health, and lifespan — on mouse genetics and one primate study, with no human administration data at all.
Human clinical evidence
- No randomised human trials. This is a research compound sold for laboratory use, and nobody has funded the trial that would change that — not because it failed one, but because there is no route to a return on it. Read the correlative and theoretical tiers as the actual evidence base rather than as a consolation prize.
📊 Correlative data
- Low circulating Klotho tracks with almost everything that gets worse with age. Observational cohorts link lower serum alpha-Klotho to chronic kidney disease progression, cardiovascular events, arterial stiffening, and poorer cognitive scores. These are associations in people who were never given Klotho, and low Klotho is downstream of kidney damage — so a large part of the signal may be reporting kidney health rather than an independent effect.
- A common variant of the KL gene (the KL-VS haplotype) associates with higher circulating Klotho and, in several cohorts, with better cognitive ageing and longer life in carriers of one copy. Notably the effect is not linear — two copies do not do better than one, which argues against reading it as a simple more-is-better dose response.
🧪 How the mechanism reads
- The mouse genetics are unusually clean, in both directions. Disrupting Klotho produces a syndrome that looks like accelerated ageing — short lifespan, vascular calcification, osteoporosis, skin atrophy — and overexpressing it extends mouse lifespan. Two-way evidence like that is rare and is the whole reason anyone cares about this protein.
- A 2023 primate study reported that a single low systemic dose of Klotho improved cognitive performance in aged rhesus monkeys, and — importantly — that a higher dose did not. A non-monotonic dose response is the opposite of what most people assume when they scale a peptide up, and it means 'more' is a specific hypothesis to test, not a safe default.
- Mechanistically it sits upstream of several pathways already targeted elsewhere in this Vault: it is required for FGF23 signalling, it suppresses insulin/IGF-1 signalling, and it inhibits Wnt. That breadth is what makes it interesting and also what makes off-target effects hard to predict.
- Nothing here has been tested in a human being. Every number for human use is an extrapolation across two species boundaries.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Klotho — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a sceptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a sceptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get Klotho
Buy Klotho at Biolongevity Labs →Klotho — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Klotho moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Klotho — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
Get the complete breakdown for Klotho — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside Klotho
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 102 markers A–Z
Klotho — frequently asked questions
What is Klotho?
Klotho (alpha-Klotho, sKlotho, long-release recombinant Klotho) is a longevity & bioregulators research compound. Alpha-Klotho is an anti-ageing protein made mostly in the kidney and the choroid plexus. A soluble form is shed into blood and CSF. It is the obligate co-receptor that lets FGF23 signal, which is how it governs phosphate and vitamin D handling, and separately it dampens insulin/IGF-1 and Wnt signalling and raises resistance to oxidative stress. Klotho falls with age and falls further in chronic kidney disease.
Is the full Klotho protocol on this page?
The reported research dose is on this page, along with how Klotho works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside the Academy.
What is the half-life of Klotho?
Klotho has an approximate half-life of Native soluble Klotho is cleared within hours; the LR construct carries an albumin-binding group intended to hold cellular activity for up to ~19 days (vendor claim, not independently published), which is part of what determines how often it's dosed.
What's the evidence behind Klotho?
Current evidence level: Theoretical — no human administration data. Klotho is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact Klotho protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →